Ultragenyx to Participate in the Cowen Health Care Conference
Ultragenyx Pharmaceutical (NASDAQ: RARE) will have its CEO, Emil D. Kakkis, participate in the Orphan CNS Panel at the Cowen 42nd Annual Health Care Conference on March 8, 2022, at 2:10 PM ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Ultragenyx Pharmaceutical (NASDAQ: RARE) will have its CEO, Emil D. Kakkis, participate in the Orphan CNS Panel at the Cowen 42nd Annual Health Care Conference on March 8, 2022, at 2:10 PM ET. The event will be accessible via a live webcast on the company’s website, with a replay available for 90 days. Ultragenyx focuses on developing therapies for rare and ultra-rare genetic diseases, boasting a diverse portfolio aimed at addressing high unmet medical needs. The management team is dedicated to efficient drug development to deliver safe and effective therapies rapidly.
Details
News Market Reaction – RARE
The recorded move for RARE in the trading session of this news was -4.95%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NOVATO, Calif., March 02, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer and President, will participate in the Orphan CNS Panel at the Cowen 42nd Annual Health Care Conference on Tuesday, March 8, 2022 at 2:10 PM ET.
The live and archived webcast of the presentation will be accessible from the company’s website at http://ir.ultragenyx.com/events.cfm. The replay of the webcast will be available for 90 days.
About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.
Contacts
Ultragenyx Pharmaceutical, Inc.
Investors
Joshua Higa
ir@ultragenyx.com
Media
Jeff Blake
415-612-7784
media@ultragenyx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.